Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 12/20 | 0.51 |
| ▸ | MME | P08473 | 1/20 | 0.51 |
| ▸ | XIAP | P98170 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 3/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 2/20 | 0.39 |
| ▸ | MMP1 | P03956 | 2/20 | 0.38 |
| ▸ | MMP3 | P08254 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5640438 | 0.85 | XIAP (0.46) | ACEMMEXIAPMMP1MMP3 | |
| SCHEMBL5638714 | 0.85 | MMP1 (0.54) | ACEMMEXIAPF2F10 | |
| SCHEMBL10941726 | 0.82 | ACE (0.59) | ACEMMEXIAPF10MMP1 | |
| SCHEMBL805251 | 0.82 | ACE (0.53) | ACEMMEXIAPF2F10 | |
| SCHEMBL5636760 | 0.80 | GAA (0.36) | ACEXIAPF10MMP1MMP3 | |
| SCHEMBL5638998 | 0.79 | ACE (0.51) | ACEMMEF2F10MMP1 | |
| SCHEMBL5638882 | 0.79 | TPSAB1 (0.56) | ACEMMEXIAPF2F10 | |
| SCHEMBL5638095 | 0.79 | RAMP1 (0.40) | ACEMMEXIAPF2PRSS1 | |
| SCHEMBL5638218 | 0.78 | SRC (0.34) | ACEMMEXIAPF2F10 | |
| SCHEMBL5638820 | 0.77 | XIAP (0.38) | ACEMMEXIAPMMP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220856-B2 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-22 | — | — | US | disclosed |
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | CCR5, CXCR3, CCR2 | ACE 1267/4885MME 1194/4885XIAP 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.